HRMY Stock Overview
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Pitolisant HD's Innovations And Critical Expansions Set To Surge Revenue And Solidify Market Dominance
Harmony Biosciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.41 |
| 52 Week High | US$40.60 |
| 52 Week Low | US$18.79 |
| Beta | 0.73 |
| 11 Month Change | -7.64% |
| 3 Month Change | 10.52% |
| 1 Year Change | 75.91% |
| 33 Year Change | -13.27% |
| 5 Year Change | n/a |
| Change since IPO | -4.32% |
Recent News & Updates
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Sep 25
Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Recent updates
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Sep 25Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Harmony Biosciences: Strong Growth At A Reasonable Price
Mar 04Our First Look At Harmony Biosciences
Nov 04Shareholder Returns
| HRMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.7% | 0.2% | 0.8% |
| 1Y | 75.9% | 23.5% | 38.3% |
Return vs Industry: HRMY exceeded the US Pharmaceuticals industry which returned 23.2% over the past year.
Return vs Market: HRMY exceeded the US Market which returned 36% over the past year.
Price Volatility
| HRMY volatility | |
|---|---|
| HRMY Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HRMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HRMY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 246 | Jeffrey Dayno | www.harmonybiosciences.com |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons.
Harmony Biosciences Holdings, Inc. Fundamentals Summary
| HRMY fundamental statistics | |
|---|---|
| Market cap | US$1.99b |
| Earnings (TTM) | US$114.99m |
| Revenue (TTM) | US$656.11m |
17.5x
P/E Ratio3.1x
P/S RatioIs HRMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRMY income statement (TTM) | |
|---|---|
| Revenue | US$656.11m |
| Cost of Revenue | US$135.08m |
| Gross Profit | US$521.03m |
| Other Expenses | US$406.04m |
| Earnings | US$114.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 29, 2024
| Earnings per share (EPS) | 2.02 |
| Gross Margin | 79.41% |
| Net Profit Margin | 17.53% |
| Debt/Equity Ratio | 34.6% |
How did HRMY perform over the long term?
See historical performance and comparison